Brain Tumor Pathology

metrics 2024

Exploring innovative solutions for brain tumor challenges.

Introduction

Brain Tumor Pathology is a pivotal peer-reviewed journal published by SPRINGER JAPAN KK, focusing on the intricate and evolving field of brain tumor research. Established in 1997, the journal serves as a crucial platform for disseminating research findings, clinical studies, and reviews that advance our understanding of brain tumors and their pathology. With a notable impact factor, it ranks in the Q2 and Q3 quartiles in multiple categories, including Cancer Research, Medicine (miscellaneous), Neurology (clinical), and Oncology, reflecting its significance in enhancing scientific discourse and clinical practice. The journal is indexed by major databases, making it accessible to a wide audience of researchers, clinicians, and students who are dedicated to unraveling the complex mechanisms of brain tumors. Although it does not currently offer open access, its comprehensive articles and studies contribute to the vital conversation on brain tumor pathologies, treatment prospects, and innovation in the field. Researchers and professionals alike will find the insights and advancements presented in Brain Tumor Pathology indispensable for guiding future studies and improving clinical outcomes.

Metrics 2024

SCIMAGO Journal Rank0.78
Journal Impact Factor2.70
Journal Impact Factor (5 years)2.60
H-Index45
Journal IF Without Self2.70
Eigen Factor0.00
Normal Eigen Factor0.17
Influence0.71
Immediacy Index0.40
Cited Half Life6.70
Citing Half Life6.50
JCI0.68
Total Documents667
WOS Total Citations762
SCIMAGO Total Citations3549
SCIMAGO SELF Citations183
Scopus Journal Rank0.78
Cites / Document (2 Years)2.58
Cites / Document (3 Years)2.76
Cites / Document (4 Years)2.71

Metrics History

Rank 2024

Scopus

Neurology (clinical) in Medicine
Rank #133/400
Percentile 66.75
Quartile Q2
Oncology in Medicine
Rank #149/404
Percentile 63.12
Quartile Q2
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #123/230
Percentile 46.52
Quartile Q3

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 110/277
Percentile 60.50
Quartile Q2
ONCOLOGY
Rank 163/322
Percentile 49.50
Quartile Q3
PATHOLOGY
Rank 31/88
Percentile 65.30
Quartile Q2

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 146/278
Percentile 47.48
Quartile Q3
ONCOLOGY
Rank 151/322
Percentile 53.11
Quartile Q2
PATHOLOGY
Rank 47/88
Percentile 46.59
Quartile Q3

Quartile History

Similar Journals

NEOPLASMA

Transforming Cancer Research into Clinical Practice
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

Oncogenesis

Leading the charge in oncogenesis research and education.
Publisher: SPRINGERNATUREISSN: 2157-9024Frequency: 1 issue/year

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

Chinese Journal of Cancer Research

Advancing cancer research for a healthier tomorrow.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Molecular & Cellular Oncology

Unraveling the complexities of cancer biology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

MOLECULAR CARCINOGENESIS

Advancing Insights into Carcinogenesis
Publisher: WILEYISSN: 0899-1987Frequency: 12 issues/year

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

Diagnostic Pathology

Elevating Diagnostics with Groundbreaking Findings
Publisher: BMCISSN: Frequency: 1 issue/year

Diagnostic Pathology is a prominent open-access journal published by BMC, dedicated to advancing the field of pathology by providing a platform for high-quality research findings since its inception in 2006. Based in the United Kingdom, the journal covers a broad spectrum of topics within the realms of histology, pathology, and forensic medicine, facilitating discussions that are crucial for both clinical and laboratory settings. With an impressive impact factor that places it in the Q2 category across multiple categories including Histology and Miscellaneous Medicine, it ranks favorably in Scopus with notable positions in the 71st and 55th percentiles for Pathology and Histology respectively. As a valuable resource for researchers, professionals, and students alike, Diagnostic Pathology promotes the dissemination of cutting-edge studies and findings, thereby contributing significantly to the evolving landscape of medical science. The journal’s commitment to open access enhances its accessibility, ensuring that valuable research is freely available to a global audience.

NEURO-ONCOLOGY

Exploring Innovative Treatments in Neuro-Oncology
Publisher: OXFORD UNIV PRESS INCISSN: 1522-8517Frequency: 12 issues/year

NEURO-ONCOLOGY, a leading journal published by OXFORD UNIVERSIT PRESS INC, is at the forefront of research in the intersection of neurology and oncology, with contributions spanning from 1999 to 2024. With a recognized impact reflected in its strong ranking, holding Q1 status in Cancer Research, Neurology (Clinical), and Oncology categories, NEURO-ONCOLOGY provides a vital platform for the dissemination of groundbreaking studies and advancements in brain tumor research and treatment. The journal ranks impressively within the 99th percentile in clinical neurology and 96th percentile in oncology, highlighting its significance and influence within the field. Accessible through institutional subscriptions, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to stay informed of the latest developments, therapeutic strategies, and scientific discussions in neuro-oncology.

Journal of Clinical and Experimental Hematopathology

Unlocking Innovations in Hematology Research.
Publisher: JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCHISSN: 1346-4280Frequency: 4 issues/year

The Journal of Clinical and Experimental Hematopathology, published by the Japanese Society of Lymphoreticular Tissue Research, is a vital resource dedicated to advancing the field of hematopathology. With an impressive Open Access model since 2019, this journal provides researchers, clinicians, and students from around the world with unfettered access to cutting-edge research and developments in hematology and pathophysiology. Based in Japan, it has established a prominent reputation in the academic community, boasting a Q3 quartile ranking in Hematology and Q1 rankings in both Medicine (Miscellaneous) and Pathophysiology as of 2023. With its innovative contributions and high visibility, the journal not only fosters scholarly discourse but also impacts clinical practices, making it an essential publication for anyone interested in the complexities of hematologic disorders. For submissions and further inquiries, the journal is located at Nagoya University Graduate School of Medicine, Japan.

CANCER CELL

Advancing the Frontiers of Cancer Research
Publisher: CELL PRESSISSN: 1535-6108Frequency: 12 issues/year

Cancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.

Head & Neck Pathology

Unveiling the Mysteries of Head & Neck Health
Publisher: SPRINGERISSN: 1936-055XFrequency: 4 issues/year

Head & Neck Pathology is a leading journal dedicated to advancing the study of pathologies affecting the head and neck region, published by Springer. With an ISSN of 1936-055X and E-ISSN of 1936-0568, this journal serves as a vital resource for the dissemination of research in oncology, otorhinolaryngology, and pathology, achieving impressive rankings of Q2 in Oncology and Q1 in both Otorhinolaryngology and Pathology & Forensic Medicine in 2023. Since its inception in 2007, Head & Neck Pathology has continued to provide a platform for innovative research findings, case studies, and reviews, fostering a deeper understanding of head and neck diseases. The journal's commitment to excellence is reflected in its rigorous peer-review process and accessibility through various academic platforms. Researchers, clinicians, and students will find valuable insights and knowledge that can enhance clinical practice and improve patient outcomes in the dynamic field of head and neck pathology.